Compare GVA & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GVA | BLTE |
|---|---|---|
| Founded | 1922 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 6.2B |
| IPO Year | 1995 | 2021 |
| Metric | GVA | BLTE |
|---|---|---|
| Price | $130.86 | $137.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $118.33 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 657.9K | 99.6K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.42% | N/A |
| EPS Growth | ★ 47.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,762,965,000.00 | N/A |
| Revenue This Year | $13.26 | N/A |
| Revenue Next Year | $6.92 | $492.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $87.72 | $56.68 |
| 52 Week High | $145.00 | $200.00 |
| Indicator | GVA | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 31.51 |
| Support Level | $116.73 | $103.94 |
| Resistance Level | $137.24 | $172.02 |
| Average True Range (ATR) | 3.75 | 7.11 |
| MACD | -1.69 | -1.16 |
| Stochastic Oscillator | 22.65 | 7.06 |
Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. The company focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges, dams, tunnels, and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, and rest from Materials segment.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.